JPRN-UMIN000023838已完成2 期
A phase II study evaluating abscopal effect of nivolumab in combination with local radiotherapy in patients with pretreated metastatic non-small cell lung cancer - A phase II study evaluating abscopal effect of nivolumab in combination with local radiotherapy in patients with pretreated metastatic non-small cell lung cancer
Department of Respiratory, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine0 个研究点目标入组 17 人开始时间: 2016年8月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Active double cancer(except for some early or cured cancer as followe:carcino ma in situ, mucosal cancer, stage I prostate, breast, or laryngeal cancer) (2) History of pericardial effusion, pleural effusion, and ascites which drainage treatment is needed (3) patients with clinically disease progression, such as obvious PS deterioration by nivolumab administration (4) radiation field includes the lung (5) Positive serum HBs antigen (6) Radiographically confirmed interstitial pneumonitis or pulmonary fibrosis (7) Patients with a clinically severe complication (8) History of severe drug allergy (9) women who are or may be pregnant or in lactatoin (10) patients judged to be unsuitable for this study by investigators
研究者
相似试验
已完成
2 期
A phase II study to investigate the efficacy of neoadjuvant erlotinib in patients with clinical stage I/II non-small cell lung cancer (NSCLC)early stage lung cancernon-small cell lung cancer stage I/II10038666NL-OMON29708Antoni van Leeuwenhoek Ziekenhuis55
进行中（未招募）
1 期
Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination with Ipilimumab vs Ipilimumab alone in Subjects with Previously Untreated, Unresectable or Metastatic Melanomanresectable or metastatic MelanomaMedDRA version: 14.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2013-002018-11-FRBristol-Myers Squibb International Corporation150
招募中
1 期
A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer.Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk FactorsMedDRA version: 21.1Level: PTClassification code: 10067946Term: Renal cell carcinoma Class: 100000004864CTIS2023-508264-29-00Bristol Myers Squibb International Corporation448
进行中（未招募）
1 期
An Immunotherapy Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy Alone in Participants with Advanced Kidney CancerEUCTR2018-004695-35-ROBristol-Myers Squibb International Corporation518
进行中（未招募）
1 期
A Study of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Participants with Advanced Kidney Cancer.Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk FactorsMedDRA version: 21.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004695-35-PLBristol-Myers Squibb International Corporation518